ZA200600176B - Combination of SRC kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases - Google Patents
Combination of SRC kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseasesInfo
- Publication number
- ZA200600176B ZA200600176B ZA200600176A ZA200600176A ZA200600176B ZA 200600176 B ZA200600176 B ZA 200600176B ZA 200600176 A ZA200600176 A ZA 200600176A ZA 200600176 A ZA200600176 A ZA 200600176A ZA 200600176 B ZA200600176 B ZA 200600176B
- Authority
- ZA
- South Africa
- Prior art keywords
- treatment
- combination
- chemotherapeutic agents
- kinase inhibitors
- proliferative diseases
- Prior art date
Links
- 102000001332 SRC Human genes 0.000 title 1
- 239000002246 antineoplastic agent Substances 0.000 title 1
- 229940127089 cytotoxic agent Drugs 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 230000002062 proliferating effect Effects 0.000 title 1
- 108010087686 src-Family Kinases Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48577903P | 2003-07-09 | 2003-07-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200600176B true ZA200600176B (en) | 2010-06-30 |
Family
ID=34135068
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200600176A ZA200600176B (en) | 2003-07-09 | 2006-01-06 | Combination of SRC kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20050009891A1 (xx) |
| EP (1) | EP1643996A4 (xx) |
| JP (1) | JP2007528849A (xx) |
| KR (1) | KR20060032627A (xx) |
| CN (1) | CN1849119A (xx) |
| AU (1) | AU2004263095B2 (xx) |
| BR (1) | BRPI0411864A (xx) |
| CA (1) | CA2531675A1 (xx) |
| GE (1) | GEP20094677B (xx) |
| IL (1) | IL173008A0 (xx) |
| IS (1) | IS8221A (xx) |
| MX (1) | MXPA06000191A (xx) |
| NO (1) | NO20060392L (xx) |
| NZ (1) | NZ544587A (xx) |
| RS (1) | RS20060011A (xx) |
| RU (1) | RU2006103858A (xx) |
| TW (1) | TW200505443A (xx) |
| UA (1) | UA83850C2 (xx) |
| WO (1) | WO2005013983A1 (xx) |
| ZA (1) | ZA200600176B (xx) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU779089B2 (en) | 1999-04-15 | 2005-01-06 | Bristol-Myers Squibb Holdings Ireland Unlimited Company | Cyclic protein tyrosine kinase inhibitors |
| US7491725B2 (en) | 2004-02-06 | 2009-02-17 | Bristol-Myers Squibb Company | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
| US7820704B2 (en) * | 2004-04-20 | 2010-10-26 | Transtech Pharma, Inc. | Substituted heteroaryl derivatives, compositions, and methods of use |
| TW200628156A (en) * | 2004-11-04 | 2006-08-16 | Bristol Myers Squibb Co | Combination of a SRC kinase inhibitor and a BCR-ABL inhibitor for the treatment of proliferative diseases |
| PE20061394A1 (es) * | 2005-03-15 | 2006-12-15 | Bristol Myers Squibb Co | Metabolitos de n-(2-cloro-6-metilfenil)-2-[[6-[4-(2-hidroxietil)-1-piperazinil]-2-metil-4-pirimidinil]amino]-5-tiazolcarboxamidas |
| US20060235006A1 (en) * | 2005-04-13 | 2006-10-19 | Lee Francis Y | Combinations, methods and compositions for treating cancer |
| DE602006021312D1 (de) * | 2005-06-09 | 2011-05-26 | Bristol Myers Squibb Co | Pharmazeutische zusammensetzung zur anwendung in der behandlung von personen mit mutant-kit-protein |
| EP1937270A1 (en) * | 2005-09-21 | 2008-07-02 | Brystol-Myers Squibb Company | Oral administration of n-(2-chloro-6-methylphenyl)-2-[[6-4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-1,3-thiazole-5-carboxamide and salts thereof |
| US20070093499A1 (en) * | 2005-10-20 | 2007-04-26 | Bristol-Myers Squibb Company | Use of dasatinib for the treatment of bone metastasis |
| US20090099197A1 (en) * | 2005-11-15 | 2009-04-16 | Bristol-Myers Squibb Company | Methods of Identifying and Treating Individuals Exhibiting MDR-1 Overexpression With Protein Tyrosine Kinase Inhibitors and Combinations Thereof |
| WO2007109527A1 (en) * | 2006-03-17 | 2007-09-27 | Bristol-Myers Squibb Company | Methods of identifying and treating individuals exhibiting mutant bcr/abl kinase polypeptides |
| JP5622393B2 (ja) * | 2006-12-15 | 2014-11-12 | アブラクシスバイオサイエンス リミテッド ライアビリティー カンパニー | トリアジン誘導体類及びそれらの治療応用 |
| GB0625691D0 (en) * | 2006-12-22 | 2007-01-31 | Astrazeneca Ab | Combination product |
| CN101265274B (zh) * | 2007-02-16 | 2013-09-04 | 中国医学科学院药物研究所 | 嘧啶噻唑胺衍生物、及其制法和药物组合物与用途 |
| US8119129B2 (en) | 2008-08-01 | 2012-02-21 | Bristol-Myers Squibb Company | Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases |
| CA2731442A1 (en) * | 2008-08-29 | 2010-03-04 | Transtech Pharma, Inc. | Substituted aminothiazole derivatives, pharmaceutical compositions, and methods of use |
| HUE033312T2 (en) * | 2009-07-20 | 2017-11-28 | Bristol Myers Squibb Co | Combination of anti CTLA4 antibody with etoposide for synergistic treatment of proliferative diseases |
| WO2014004376A2 (en) | 2012-06-26 | 2014-01-03 | Del Mar Pharmaceuticals | Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof |
| CN116808044A (zh) | 2018-06-15 | 2023-09-29 | 汉达癌症医药责任有限公司 | 激酶抑制剂的盐类及其组合物 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5051910A (en) * | 1989-10-16 | 1991-09-24 | Honeywell Inc. | Wind forecast error compensation for 4-D guidance in a aircraft flight management system |
| US5121325A (en) * | 1990-04-04 | 1992-06-09 | Smiths Industries Aerospace & Defense Systems, Inc. | Required time of arrival (RTA) control system |
| ZA200007412B (en) * | 1998-05-15 | 2002-03-12 | Imclone Systems Inc | Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases. |
| US7125875B2 (en) | 1999-04-15 | 2006-10-24 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
| AU779089B2 (en) * | 1999-04-15 | 2005-01-06 | Bristol-Myers Squibb Holdings Ireland Unlimited Company | Cyclic protein tyrosine kinase inhibitors |
| US6507782B1 (en) * | 2001-05-14 | 2003-01-14 | Honeywell International Inc. | Aircraft control system for reaching a waypoint at a required time of arrival |
| CN1523991A (zh) | 2001-08-10 | 2004-08-25 | ��˹��ŵ�� | 单独的c-Src抑制剂或其与STI571的组合用于治疗白血病的用途 |
| US20040209930A1 (en) | 2002-10-02 | 2004-10-21 | Carboni Joan M. | Synergistic methods and compositions for treating cancer |
| US7652146B2 (en) * | 2004-02-06 | 2010-01-26 | Bristol-Myers Squibb Company | Process for preparing 2-aminothiazole-5-carboxamides useful as kinase inhibitors |
| US20050215795A1 (en) | 2004-02-06 | 2005-09-29 | Bang-Chi Chen | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
-
2004
- 2004-07-08 US US10/886,955 patent/US20050009891A1/en not_active Abandoned
- 2004-07-09 KR KR1020067000300A patent/KR20060032627A/ko not_active Application Discontinuation
- 2004-07-09 GE GEAP20049207A patent/GEP20094677B/en unknown
- 2004-07-09 AU AU2004263095A patent/AU2004263095B2/en not_active Ceased
- 2004-07-09 EP EP04777765A patent/EP1643996A4/en not_active Withdrawn
- 2004-07-09 RU RU2006103858/04A patent/RU2006103858A/ru not_active Application Discontinuation
- 2004-07-09 MX MXPA06000191A patent/MXPA06000191A/es not_active Application Discontinuation
- 2004-07-09 CA CA002531675A patent/CA2531675A1/en not_active Abandoned
- 2004-07-09 WO PCT/US2004/021890 patent/WO2005013983A1/en active Application Filing
- 2004-07-09 JP JP2006518903A patent/JP2007528849A/ja active Pending
- 2004-07-09 RS YUP-2006/0011A patent/RS20060011A/sr unknown
- 2004-07-09 CN CNA2004800259078A patent/CN1849119A/zh active Pending
- 2004-07-09 UA UAA200601309A patent/UA83850C2/ru unknown
- 2004-07-09 TW TW093120688A patent/TW200505443A/zh unknown
- 2004-07-09 BR BRPI0411864-2A patent/BRPI0411864A/pt not_active IP Right Cessation
- 2004-07-09 NZ NZ544587A patent/NZ544587A/en unknown
-
2006
- 2006-01-06 ZA ZA200600176A patent/ZA200600176B/xx unknown
- 2006-01-06 IS IS8221A patent/IS8221A/is unknown
- 2006-01-08 IL IL173008A patent/IL173008A0/en unknown
- 2006-01-24 NO NO20060392A patent/NO20060392L/no not_active Application Discontinuation
-
2008
- 2008-03-13 US US12/047,623 patent/US7622472B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2531675A1 (en) | 2005-02-17 |
| BRPI0411864A (pt) | 2006-08-08 |
| MXPA06000191A (es) | 2006-04-11 |
| NZ544587A (en) | 2009-07-31 |
| KR20060032627A (ko) | 2006-04-17 |
| US7622472B2 (en) | 2009-11-24 |
| TW200505443A (en) | 2005-02-16 |
| JP2007528849A (ja) | 2007-10-18 |
| US20050009891A1 (en) | 2005-01-13 |
| WO2005013983A1 (en) | 2005-02-17 |
| RS20060011A (xx) | 2007-12-31 |
| EP1643996A1 (en) | 2006-04-12 |
| NO20060392L (no) | 2006-02-03 |
| IL173008A0 (en) | 2006-06-11 |
| IS8221A (is) | 2006-01-06 |
| GEP20094677B (en) | 2009-05-10 |
| UA83850C2 (ru) | 2008-08-26 |
| EP1643996A4 (en) | 2009-06-03 |
| AU2004263095A1 (en) | 2005-02-17 |
| CN1849119A (zh) | 2006-10-18 |
| AU2004263095B2 (en) | 2009-10-29 |
| US20080153842A1 (en) | 2008-06-26 |
| RU2006103858A (ru) | 2006-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200600176B (en) | Combination of SRC kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases | |
| EP1812432A4 (en) | COMBINATION OF AN SRC KINASE INHIBITOR AND A BCR ABL INHIBITOR FOR THE TREATMENT OF PROLIFERATIVE DISEASES | |
| HK1139036A1 (en) | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases | |
| EP1664051A4 (en) | PYRROLOPYRIDAZINE COMPOUNDS AND METHODS OF USING SAME FOR TREATING PROLIFERATION DISORDERS | |
| ZA200700223B (en) | Quinazolin-4-yl-piperidine and cinnolin-4-yl-peperidine derivatives as PDE10 inhibitors for the treatment of CNS disorders | |
| AU2003223380A8 (en) | Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders | |
| HK1086488A1 (en) | Compound and use thereof for the treatment of cancer | |
| IL176233A0 (en) | Organophosphorous indazole derivatives and use thereof as protein kinase inhibitors | |
| IL178860A (en) | Certain chemical entities, preparations and processes | |
| PL373912A1 (en) | Heterocyclic derivatives for the treatment of cancer and other proliferative diseases | |
| HK1075844A1 (en) | Formulation and methods for the treatment of thrombocythemia | |
| SI1627639T1 (sl) | Uporaba inhibitorjev COX-2 za zdravljenje afektivnih motenj | |
| IL183656A0 (en) | Indenyl derivatives and use thereof for the treatment of neurological disorders | |
| AU2003243561A1 (en) | Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases | |
| IL172018A0 (en) | Enalapril-nitroxyderivatives derivatives and related compounds as ace inhibitors for the treatment of cardiovascular diseases | |
| PT1487828E (pt) | Derivados de morfolinil-ureia para utilização no tratamento de doenças inflamatórias | |
| GB0321384D0 (en) | Pteridine derivatives for the treatment of septic shock and TNF-alpha- related diseases | |
| AU2003210983A8 (en) | Kinase inhibitors and methods of use thereof | |
| ZA200606065B (en) | Acidic quinoline derivatives and their use for the prevention and/or treatment of hyperglycaemia-related pathologies | |
| ZA200704971B (en) | Pyrid-2-ones useful as inhibitors of Tec family protein kinases for the treatment of inflammatory, proliferative and immunologically-mediated diseases | |
| PL369736A1 (en) | New medicinal compositions on the basis of anticholinergic agents and egfr kinase inhibitors | |
| GB2410744B (en) | Kinase inhibitors for the treatment of disease | |
| EP1684795A4 (en) | METHODS AND AGENTS FOR THE TREATMENT OF CANCER | |
| SI1680405T1 (sl) | Bengamidni derivati in njihova uporaba za zdravljenje rakavih bolezni | |
| IL175611A0 (en) | Combinations for the treatment of proliferative diseases |